KR100455531B1 - 티클로피딘을 활성성분으로 함유하는 각막 혈관신생억제조성물과 그 제조방법 - Google Patents
티클로피딘을 활성성분으로 함유하는 각막 혈관신생억제조성물과 그 제조방법 Download PDFInfo
- Publication number
- KR100455531B1 KR100455531B1 KR10-2001-0070330A KR20010070330A KR100455531B1 KR 100455531 B1 KR100455531 B1 KR 100455531B1 KR 20010070330 A KR20010070330 A KR 20010070330A KR 100455531 B1 KR100455531 B1 KR 100455531B1
- Authority
- KR
- South Korea
- Prior art keywords
- ticlopidine
- corneal
- corneal angiogenesis
- present
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
- 삭제
- 티클로피딘을 활성성분으로 함유하는 혈관신생억제 조성물의 제조방법에 있어서,하이드론(hydroxyethylmethacrylate)을 에틸알콜에 용해하여 하이드론의 농도가 24 %인 하이드론 용해액을 제조한 다음,이 하이드론 용해액에 티클로피딘을 첨가하고 용해하여 티클로피딘의 농도가 1 ~ 5 mM 이며, 각막혈관신생억제 효과를 나타내는 조성물을 제조하는 것으로 구성된,티클로피딘을 활성성분으로 함유하는 각막혈관신생억제 조성물의 제조방법.
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0070330A KR100455531B1 (ko) | 2001-11-13 | 2001-11-13 | 티클로피딘을 활성성분으로 함유하는 각막 혈관신생억제조성물과 그 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0070330A KR100455531B1 (ko) | 2001-11-13 | 2001-11-13 | 티클로피딘을 활성성분으로 함유하는 각막 혈관신생억제조성물과 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030039420A KR20030039420A (ko) | 2003-05-22 |
KR100455531B1 true KR100455531B1 (ko) | 2004-11-15 |
Family
ID=29569123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0070330A KR100455531B1 (ko) | 2001-11-13 | 2001-11-13 | 티클로피딘을 활성성분으로 함유하는 각막 혈관신생억제조성물과 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100455531B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230060087A (ko) | 2021-10-27 | 2023-05-04 | 중앙대학교 산학협력단 | Egf 또는 egf 처리 대식세포 유래 엑소좀을 유효성분으로 포함하는 각막질환 예방 또는 치료용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020010230A (ko) * | 2000-07-28 | 2002-02-04 | 김민영 | 5-[(2-클로로페닐)메틸]-4,5,6,7-테트라히드로티에노[3,2-c]피리딘 또는 그의 염산염인 티클로피딘의혈관신생억제제로서의 용도 |
-
2001
- 2001-11-13 KR KR10-2001-0070330A patent/KR100455531B1/ko active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020010230A (ko) * | 2000-07-28 | 2002-02-04 | 김민영 | 5-[(2-클로로페닐)메틸]-4,5,6,7-테트라히드로티에노[3,2-c]피리딘 또는 그의 염산염인 티클로피딘의혈관신생억제제로서의 용도 |
Non-Patent Citations (2)
Title |
---|
Klein-Soyer C, et al, Biol Cell. Jul. 1997 * |
Klein-Soyer C. et al, J. Cell. Physiol, Aug.1994 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230060087A (ko) | 2021-10-27 | 2023-05-04 | 중앙대학교 산학협력단 | Egf 또는 egf 처리 대식세포 유래 엑소좀을 유효성분으로 포함하는 각막질환 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20030039420A (ko) | 2003-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11013719B2 (en) | Sunitinib formulations and methods for use thereof in treatment of glaucoma | |
Bian et al. | Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye | |
Wu et al. | Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis | |
Topete et al. | Dual drug delivery from hydrophobic and hydrophilic intraocular lenses: in-vitro and in-vivo studies | |
JP2002047186A (ja) | 眼部前段および眼部表面の免疫関連性疾病用治療薬物 | |
WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
JP7473237B2 (ja) | 眼乾燥症候群および他の外傷を受けた非角化上皮表面を処置する組成物および方法 | |
Chen et al. | Effect of etanercept on post-traumatic proliferative vitreoretinopathy | |
KR100835002B1 (ko) | 안과 국소 투여용 마크롤라이드계 약제 조성물 | |
Velez et al. | SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell–induced rabbit models | |
JP3603129B2 (ja) | 糖尿病性角膜症の治療剤 | |
Wang et al. | A preliminary study to treat severe endophthalmitis via a foldable capsular vitreous body with sustained levofloxacin release in rabbits | |
JPH05213743A (ja) | 白内障治療剤 | |
CN1233172A (zh) | 继发性白内障抑制剂 | |
KR100455531B1 (ko) | 티클로피딘을 활성성분으로 함유하는 각막 혈관신생억제조성물과 그 제조방법 | |
Min et al. | Comparison of single versus multiple injections of the protein saratin for prolonging bleb survival in a rabbit model | |
RU2134107C1 (ru) | Препарат "гистохром" для лечения воспалительных заболеваний сетчатки и роговицы глаз | |
CN111991391A (zh) | 黄连素在治疗或预防非感染性眼表炎症中的用途 | |
Pilkerton et al. | Experimental vitreous fibroplasia following perforating ocular injuries | |
Bao et al. | Effect of an MG132-sustained drug delivery capsular ring on the inhibition of posterior capsule opacification in a rabbit model | |
KR101736342B1 (ko) | 인삼추출물을 유효성분으로 하는 안과질환 치료용 조성물 | |
EP1161256A1 (en) | Use of nerve growth factor for therapy of intraocular tissue pathologies | |
CN114246879B (zh) | 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途 | |
US20210283174A1 (en) | Oxygenated emulsion for treatment of ocular injury | |
EP1993563A2 (en) | Pharmaceutical latrunculin formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121019 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20131017 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150810 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160901 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170830 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20180903 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190822 Year of fee payment: 16 |